0.15Open0.15Pre Close0 Volume261 Open Interest3.50Strike Price0.00Turnover87.30%IV-1.82%PremiumJan 17, 2025Expiry Date0.21Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7475Delta1.1226Gamma13.16Leverage Ratio-0.0128Theta-0.0002Rho-9.84Eff Leverage0.0010Vega
Revance Therapeutics Stock Discussion
Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.
Monday, 13th January at 8:30 am
JOHNSON CITY, Tenn., Jan. 13, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that, at the request of Revance Therapeutics, Inc., ("Revance") (NASDAQ: RVNC), it has extended the expiration of its cash tender offer to acquire all of the issued and outstand...
Dow Jones· 1 min ago
Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash
Monday, 6th January at 9:00 am
Compelling Cash Proposal Provides 16% Premium Over Revance's Amended and Restated Agreement with Crown Laboratories
GENEVA, Jan. 6, 2025 /PRNewswire/ -- Teoxane SA today announced that on January 6, 2025, it submitted a proposal to the Board of Directors of Revance Therapeutics, Inc. (NASDAQ: RVNC) to acquire Revance for $3.60 per s...
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
No comment yet